Salma Jabbour, MD, on the Results of the Ongoing KEYNOTE-799 Study

Video

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed updated results from the study of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.

Results from the ongoing KEYNOTE-799 study (NCT03631784) presented at the IASLC 2020 World Conference on Lung Cancer (WCLC) Singapore showed promise for the use of pembrolizumab (Keytruda) plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer (NSCLC).

With approximately 15 weeks of follow-up, previous interim results demonstrated an overall response rate (ORR) of 67.0% in cohort A, which contained patients with both squamous and nonsquamous NSCLC, and 56.6% in cohort B, which consisted of only patients with nonsquamous NSCLC.

In an interview with CancerNetwork®, Salma Jabbour, MD, chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey, discussed the updated results presented at WCLC which reported data with an additional 6 months of follow-up.

Transcription:

The 1-year PFS [rate] in cohort A was about 67%. And in cohort B, the 1-year PFS [rate] was about 65%. The objective response rate was about 70% in both groups with a duration of response which was not yet reached. In addition, the 1-year overall survival was over 80% in both cohort[s] A and B. Overall, the results were very promising for this study.

Reference:

Reck M, Lee KH, Frost N, et al. Pembrolizumab plus platinum chemotherapy and radiotherapy in unresectable, locally advanced, stage III NSCLC: KEYNOTE-799. Presented at the IASLC 2020 World Conference on Lung Cancer Singapore. Abstract OA02.03.

Related Videos
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.
According to Thomas E. Hutson, DO, PharmD, FACP, 4-year follow-up data from the phase 3 CLEAR study confirm the maintained benefits of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Rana R. McKay, MD discusses presentations of interest that were presented at the 2023 Kidney Cancer Research Summit, including a discussion on how PET imaging may identify which patients with renal cell carcinoma may respond to immunotherapy.
A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.
Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.
Expert on NSCLC